An investigation for investors in Novavax, Inc. (NASDAQ:NVAX) shares over potential securities laws violations by Novavax, Inc. was announced and NASDAQ:NVAX stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/24/2018 -- An investigation was announced for investors of Novavax, Inc. over potential securities laws violations by Novavax, Inc. in connection with certain financial statements.
Investors who purchased shares of Novavax, Inc. (NASDAQ:NVAX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Novavax, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
In November 2017, Novavax, Inc. projected a year-end release for top-line data from the Company's Phase 1/2 clinical trial of its NanoFlu Vaccine. Then, on December 19, 2017, Novavax, Inc. announced that a "complete package" will not be completed and released until February 2018. Novavax, Inc. advised investors that "the wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability."
Those who purchased shares of Novavax, Inc. (NASDAQ:NVAX) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com